Already a DIA Member? Sign in. Not a member? Join.
Sign in
Forgot User ID? or Forgot Password?
Not a Member?
Create Account and Join
First time here? Explore the benefits of becoming a member.
Capital Hilton
Oct 28, 2024 7:00 AM - Oct 30, 2024 7:00 PM
1001 16th Street NW, , Washington, DC 20036-5794 , USA
DAYS
HOURS
MINUTES
SECONDS
Need Approval in Order to Attend?
Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.
Three Track Meeting!
There are more than a dozen oligonucleotide based products approved for therapeutic use and nearly 100 currently in clinical testing. Track 1 will explore the lessons learned and the ongoing challenges to clinical use of oligos.
The nonclinical track will focus on development and safety assessments of oligonucleotide-based therapeutics.
This track provides an interactive forum for innovators and regulators to present and discuss cutting edge topics in oligonucleotide chemistry, manufacturing, and controls (CMC). The track emphasizes topics that are emerging and will require ongoing collaboration with global regulators. Attendees will take away a deeper understanding of key developments, along with insight into current challenges and successful strategies for navigating this complex area.
Have an account?
Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.
This website uses cookies. Click accept cookies to continue. Or you can disable cookies, but it will affect your experience. Learn more.